Skip to content

Intraocular Pressure Measured by a Novel Sensing Contact Lens Versus Tonometry

A Prospective Single Center Open Label Study Assessing Intraocular Pressure Measurements Using a Novel Sensing Contact Lens-based Device as Compared to Standard Tonometry, in Open Angle Glaucoma and Ocular Hypertensive Patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04024293
Enrollment
12
Registered
2019-07-18
Start date
2025-10-01
Completion date
2026-05-01
Last updated
2026-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Ocular Hypertension

Brief summary

While elevated intraocular pressure (IOP) is no longer part of the definition of glaucoma it remains the sole proven modifiable risk factor for the onset and progression of glaucoma. IOP is known to vary with the time of day as well as with daily activities. The importance of the nycthemeral IOP pattern for successful management of glaucoma has been well documented, especially for patients who experience visual loss despite apparently normal and/or controlled IOP during office hours. The current way of assessing nycthemeral IOP fluctuation is to perform repeated discrete tonometry measurements, once per hour in the best cases. Since its development in the 50s, Goldmann applanation tonometry (GAT) has remained the gold standard method for measuring IOP, despite its limitations. However, tonometry may be an imperfect method for measuring changes in IOP because it allows only snapshot and non-continuous measurements, it is not physiologic and disturbs the sleep architecture. There have been many efforts in the past decades to search for an ambulatory and frequent method to monitor IOP for 24 hours. In this context, Sensimed AG has recently developed a sensing contact lens-based device intended to measure IOP over 24 hours, the Goldfish (GF). First-in-man data obtained with this device showed agreements between IOP measured by GF and values obtained by standard tonometry in the same eye, comparable to literature results for routinely used tonometry devices. However, this pilot study included 9 subjects only with improvable safety, tolerability and efficacy profiles. The main goal of this study is to assess IOP measurements with the GF and compare the values with those obtained by standard tonometry in patients with open angle glaucoma (OAG) and ocular hypertension (OHT).

Interventions

DEVICEGoldfish (GF)

The GF lens (SCL) will be place on participant's eye for a 24h IOP recording session

Sponsors

Sensimed AG
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Informed Consent * A clinical diagnosis of primary open angle glaucoma (POAG), including normal tension glaucoma (NTG), for OAG patients * A clinical diagnosis of OHT, for OHT patients * For all patients: Open angles on gonioscopy Aged ≥ 18 years, either gender Both central corneal radii (CCR) between 7.3mm (46.23D) and 8.05mm (41.93D), with a maximum difference of 2D between the 2 radii in the study eye Central corneal thickness (CCT) between 490µm and 600µm in the study eye

Exclusion criteria

* Ocular pathology (other than glaucoma or OHT) * Previous glaucoma, cataract or refractive laser/surgery * Corneal or conjunctival abnormality, precluding contact lens adaptation * Insufficiency of lacrimal secretion * Subjects with allergy to corneal anesthetic * Subjects with contraindications for silicone contact lens wear * Subjects with contraindications for Diamox or Latanoprost or Timolol * Skin irritations, skin eczema or other indications against the wearing of adhesive patches * Subjects unable or unwilling to comply with the study procedures * Subjects lacking the capacity to consent (vulnerable persons) * Subjects with history of cardiac failure, treated cardiopathy or renal failure * Subjects with known cognitive disorders * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant, * Participation in another study with investigational drug within the 30 days preceding and during the present study, * Enrolment of the investigator, his/her family members, employees and other dependent persons.

Design outcomes

Primary

MeasureTime frameDescription
GF IOP measurement as compared to IOP24 hoursDifferences between GF IOP measurements at the recording start/end and the values obtained by GAT before/after GF SCL placement/removal, in the same eye

Countries

Switzerland

Contacts

CONTACTKaweh Mansouri, Pr
kwmansouri@gmail.com+41 21 619 36 02
PRINCIPAL_INVESTIGATORKaweh Mansouri, Pr

Swiss Glaucoma Foundation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 1, 2026